### ü´Ä Atrial Fibrillation: Initial Rate Control

#### ‚úÖ True Statements
1. **Œ≤-blockers** and **nondihydropyridine calcium channel blockers** are first-line agents for ventricular rate control in **atrial fibrillation (AF)**.
2. **Metoprolol**, a Œ≤-blocker, is appropriate for initial rate control in AF, especially in patients with **chronic kidney disease** or **left ventricular (LV) dysfunction**.
3. **Digoxin** is a second-line agent for rate control in AF and is typically used as **add-on therapy** when Œ≤-blockers or calcium channel blockers are insufficient.
4. **Direct current cardioversion (DCCV)** is reserved for **unstable patients**, those with a known AF duration of less than 48 hours, or those who have received **adequate anticoagulation**.
5. In **stable patients with atrial fibrillation (AF)** of unknown or prolonged duration, at least **4 weeks of anticoagulation** or **imaging to exclude left atrial thrombus** is required before cardioversion.
6. **Uncontrolled AF with rapid ventricular rate**, even in asymptomatic patients, poses a risk for **tachycardia-induced cardiomyopathy**, necessitating rate control.
7. Target heart rate in AF management is between **60/min and 110/min** to prevent complications and alleviate symptoms.

#### üí¨ Extra
1. The choice between Œ≤-blockers and calcium channel blockers depends on comorbid conditions; for example, calcium channel blockers should be avoided in patients with **LV dysfunction**.
2. **Digoxin toxicity** is more common in patients with **impaired renal function**, making it less favorable as a first-line agent in such populations.
4. Cardioversion without prior anticoagulation is contraindicated due to the risk of **thromboembolism**, unless a **left atrial thrombus** is ruled out by imaging.

#### üè∑Ô∏è Tags
#Cardiology #AtrialFibrillation #RateControl #Metoprolol #Digoxin #DirectCurrentCardioversion #TachycardiaInducedCardiomyopathy #Anticoagulation

#### üìö Reference
January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol.* 2019;74:104-132. PMID: [30703431](https://pubmed.ncbi.nlm.nih.gov/30703431) doi: [10.1016/j.jacc.2019.01.011](https://doi.org/10.1016/j.jacc.2019.01.011)

#### üÜî Question ID
CVMCQ24115

#### üïí Last Updated
January 2025